cell
end
viral
content
reach
cytosol
genet
unrel
virus
subvert
analog
subcellular
mechan
use
similar
traffick
pathway
success
entri
antivir
strategi
target
earli
step
infect
therefor
appeal
particularli
probabl
success
interfer
common
step
highest
describ
potent
inhibitori
effect
content
releas
infect
chimer
vsv
contain
envelop
protein
ebov
vsvebov
elicit
apilimod
small
molecul
inhibitor
main
endosom
kinas
pikfyv
also
describ
potent
inhibit
strain
apilimod
result
defin
new
tool
studi
intracellular
traffick
pathogen
elicit
inhibit
pikfyv
kinas
suggest
potenti
target
kinas
develop
smallmolecul
antivir
certifi
peer
review
membraneenvelop
virus
deliv
content
cell
via
envelop
catalyz
membran
fusion
bind
viru
specif
host
cell
receptor
trigger
membran
fusion
occur
directli
plasma
membran
follow
endocyt
uptak
virus
requir
endocyt
uptak
use
differ
initi
traffick
rout
reach
site
membran
fusion
endosom
acid
ph
serv
trigger
conform
rearrang
viral
envelop
protein
catalyz
membran
fusion
seen
influenza
viru
iav
vesicular
stomat
viru
block
pikfyv
kinas
downstream
effect
virus
even
though
requir
interact
membran
fusion
apilimod
also
inhibit
infect
authent
strain
viru
slightli
lower
suggest
apilimod
pass
safeti
test
previou
human
clinic
trial
nonvir
indic
potenti
start
point
develop
smallmolecul
entri
inhibitor
could
limit
infect
diseas
pathogenesi
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
apilimod
treatment
svga
cell
led
enlarg
vacuol
endosom
lysosom
tag
fluoresc
fig
agreement
earlier
pikfyv
ablat
studi
vsvmegfp
fluoresc
dot
white
reach
tag
speci
enlarg
endolysosom
success
penetr
cytosol
indic
megfp
nuclear
margin
fig
zebov
also
traffick
tag
speci
enlarg
endolysosom
often
reach
one
numer
vacuol
enrich
fig
megfpzebov
endosom
increas
presenc
apilimod
test
effect
apilimod
bona
fide
infect
expos
vero
cell
fulli
infecti
strain
h
incub
supernat
harvest
titter
focusform
assay
separ
set
vero
cell
fig
apilimod
strongli
inhibit
infect
doserespons
curv
similar
better
observ
vsvegfpzebov
nm
fig
autoimmun
condit
drug
test
suggest
one
compound
potenti
deriv
would
candid
broadspectrum
therapeut
sever
emerg
human
viral
pathogen
includ
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
